Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Foghorn Therapeutics Inc (FHTX)

Foghorn Therapeutics Inc (FHTX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 354,481
  • Shares Outstanding, K 41,802
  • Annual Sales, $ 1,320 K
  • Annual Income, $ -101,320 K
  • 60-Month Beta 1.88
  • Price/Sales 21.88
  • Price/Cash Flow N/A
  • Price/Book 14.14
Trade FHTX with:

Options Overview Details

View History
  • Implied Volatility 96.83% ( +0.52%)
  • Historical Volatility 100.35%
  • IV Percentile 22%
  • IV Rank 12.84%
  • IV High 282.20% on 10/11/22
  • IV Low 69.53% on 11/08/22
  • Put/Call Vol Ratio 0.00
  • Today's Volume 0
  • Volume Avg (30-Day) 9
  • Put/Call OI Ratio 0.01
  • Today's Open Interest 1,051
  • Open Int (30-Day) 1,057

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/22
See More
  • Average Estimate -0.59
  • Number of Estimates 4
  • High Estimate -0.33
  • Low Estimate -0.74
  • Prior Year -0.77
  • Growth Rate Est. (year over year) +23.38%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.32 +57.52%
on 12/28/22
9.85 -14.92%
on 01/12/23
+2.68 (+47.02%)
since 12/23/22
3-Month
5.32 +57.52%
on 12/28/22
9.85 -14.92%
on 01/12/23
+0.13 (+1.58%)
since 10/26/22
52-Week
5.32 +57.52%
on 12/28/22
18.12 -53.75%
on 08/12/22
-6.49 (-43.64%)
since 01/26/22

Most Recent Stories

More News
Foghorn Therapeutics Inc. (FHTX) Reports Q3 Loss, Misses Revenue Estimates

Foghorn Therapeutics Inc. (FHTX) delivered earnings and revenue surprises of -3.33% and 30.77%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the...

FHTX : 8.38 (-1.18%)
SCYX : 1.7500 (+1.74%)
Can Foghorn Therapeutics Inc. (FHTX) Climb 161% to Reach the Level Wall Street Analysts Expect?

The consensus price target hints at a 161.2% upside potential for Foghorn Therapeutics Inc. (FHTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in...

FHTX : 8.38 (-1.18%)
Cellarity Announces Close of $121 Million Series C Financing

Cellarity , a life sciences company founded by Flagship Pioneering to transform the way medicines are created, announced today the completion of a $121 million Series C financing, bringing its total funding...

DNLI : 30.53 (-0.91%)
EVLO : 1.0200 (-7.27%)
FHTX : 8.38 (-1.18%)
MRNA : 193.24 (+0.09%)
OMGA : 7.76 (+0.13%)
RUBY : 0.2800 (+4.21%)
SANA : 4.61 (-1.71%)
MCRB : 5.51 (+1.57%)
Biotech Stock Roundup: GILD, BLUE, AXSM's Drug Approvals, FHTX Study Update & More

Regulatory updates from Gilead (GILD) and Axsome (AXSM) are a few key highlights from the biotech sector during the past week.

GILD : 83.62 (-0.54%)
NVAX : 10.98 (-1.17%)
BLUE : 6.23 (-1.58%)
AXSM : 71.50 (-3.35%)
FHTX : 8.38 (-1.18%)
Foghorn (FHTX) Phase I AML/MDS Study on Full Clinical Hold

Foghorn (FHTX) receives yet another setback as the phase I dose escalation study of FHD-286 in relapsed and/or refractory AML and MDS has been put on full clinical hold.

DVAX : 11.78 (-0.25%)
LLY : 348.01 (-0.49%)
FHTX : 8.38 (-1.18%)
BOLT : 1.4600 (-2.01%)
Cellarity Releases Novel, Open-Source, Single-Cell Dataset and Invites the Machine Learning and Computational Biology Communities to Develop New Algorithms Capable of Learning Fundamental Rules of Cell Behavior

Cellarity , a life sciences company founded by Flagship Pioneering to transform the way medicines are created, announced today the release of a unique single-cell dataset to accelerate innovation in mapping...

DNLI : 30.53 (-0.91%)
EVLO : 1.0200 (-7.27%)
FHTX : 8.38 (-1.18%)
MRNA : 193.24 (+0.09%)
OMGA : 7.76 (+0.13%)
RUBY : 0.2800 (+4.21%)
SANA : 4.61 (-1.71%)
MCRB : 5.51 (+1.57%)
Foghorn Therapeutics Inc. (FHTX) Reports Q2 Loss, Misses Revenue Estimates

Foghorn Therapeutics Inc. (FHTX) delivered earnings and revenue surprises of -24.53% and 68.77%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?...

FHTX : 8.38 (-1.18%)
RVLP : 1.3900 (+11.20%)
Foghorn Therapeutics Provides Second Quarter 2022 Financial and Corporate Update

- FHD-286 dose escalation Phase 1 study in metastatic uveal melanoma continues to progress per protocol; working to resolve partial clinical hold in AML...

FHTX : 8.38 (-1.18%)
Foghorn Therapeutics Announces Participation in Upcoming Investor Conferences

CAMBRIDGE, Mass., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a...

FHTX : 8.38 (-1.18%)
Michael Severino, M.D., Joins Flagship Pioneering-Founded Tessera Therapeutics as Chief Executive Officer

Flagship Pioneering, the bioplatform innovation company, and Tessera Therapeutics, the biotechnology company pioneering GENE WRITING technology, today announced that Michael Severino, M.D., has joined...

DNLI : 30.53 (-0.91%)
EVLO : 1.0200 (-7.27%)
FHTX : 8.38 (-1.18%)
MRNA : 193.24 (+0.09%)
OMGA : 7.76 (+0.13%)
RUBY : 0.2800 (+4.21%)
SANA : 4.61 (-1.71%)
MCRB : 5.51 (+1.57%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Foghorn Therapeutics Inc. engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system. Foghorn Therapeutics Inc. is based in CAMBRIDGE, Mass.

See More

Key Turning Points

3rd Resistance Point 8.99
2nd Resistance Point 8.83
1st Resistance Point 8.61
Last Price 8.38
1st Support Level 8.23
2nd Support Level 8.07
3rd Support Level 7.85

See More

52-Week High 18.12
Fibonacci 61.8% 13.23
Fibonacci 50% 11.72
Fibonacci 38.2% 10.21
Last Price 8.38
52-Week Low 5.32

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar